Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026

(Neutral)

Rhea-AI Summary

Spyre Therapeutics (NASDAQ: SYRE) will report SPY001 Part A induction topline results from the SKYLINE trial in moderate-to-severe ulcerative colitis on Monday, April 13, 2026.

The company will host a conference call and webcast at 8:00am ET on April 13, 2026 to discuss the results; archived access will be available via Spyre's Investor Relations site.

News Market Reaction – SYRE

+23.36%

+23.36% Session close to close

In the Apr 13 session, SYRE gained 23.36%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +23.4% in the session following this news. A strong positive reaction aligns with S...

Analysis

The stock surged +23.4% in the session following this news. A strong positive reaction aligns with Spyre’s pattern of favorable responses to pipeline and data-timing updates, as seen after the Feb 19, 2026 corporate update and the Mar 16, 2026 SKYWAY acceleration. However, an effective shelf for up to $500,000,000 and an unused $154,059,875 ATM program represent potential future equity supply that could temper extended upside following the SPY001 SKYLINE Part A topline results.

Key Figures

Topline date: April 13, 2026 Conference call time: 8:00am ET Cash and securities: $756.5 million +5 more

8 metrics

Topline date April 13, 2026 Scheduled SPY001 Part A induction topline from SKYLINE trial

Conference call time 8:00am ET Scheduled call to discuss SPY001 SKYLINE Part A results

Cash and securities $756.5 million Balance as of Dec 31, 2025; runway into H2 2028

Equity raise $316.2 million Gross proceeds from October 2025 financing

Shelf capacity $500,000,000 Maximum aggregate amount under S-3 shelf registration

ATM program size $154,059,875 Maximum common stock under TD Cowen at-the-market agreement

Current price $51.77 Price before SPY001 SKYLINE Part A topline call announcement

52-week range $10.91–$54.39 SYRE 52-week low and high before this news

Historical Context

5 past events · Latest: Apr 03 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 03	Inducement awards	Neutral	+2.9%	Granted 70,200 stock options to new non-executive employees.
Mar 16	Pipeline timeline update	Positive	+9.3%	Accelerated SKYWAY RA topline to Q3 2026 and confirmed SKYLINE timelines.
Mar 06	Inducement awards	Neutral	+2.3%	Announced stock option grants totaling 46,600 shares to two employees.
Feb 24	Investor conferences	Neutral	+1.0%	Planned participation in three March 2026 healthcare investor conferences.
Feb 19	Earnings and update	Positive	+14.3%	Reported 2025 results, strong cash and multiple 2026 proof-of-concept readouts.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news, especially data and corporate updates, has generally been followed by positive next-day price reactions.

Recent Company History

Over the past few months, Spyre has steadily advanced its pipeline and corporate agenda. On Feb 19, 2026, it reported 2025 results, highlighting $756.5 million in cash and plans for six 2026 proof-of-concept readouts, with a 14.28% next-day move. Subsequent items included investor conferences, multiple inducement grants, and accelerated SKYWAY readouts. Today’s announcement of an upcoming SKYLINE SPY001 Part A topline call fits this cadence of sequential data milestones.

Key Terms

ulcerative colitis

1 terms

ulcerative colitis medical

"SKYLINE trial in moderate-to-severely active ulcerative colitis patients on Monday"

A long-term inflammatory disease that causes repeated sores and irritation in the large intestine, leading to symptoms such as abdominal pain, urgent diarrhea, and fatigue. For investors, it matters because the condition creates a steady need for effective treatments, influences the size of drug and medical-device markets, and makes clinical trial results, regulatory decisions and treatment approvals material to companies’ revenue prospects—like watching for fixes to a recurring leak in an important building system.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

04/10/2026 - 04:05 PM

WALTHAM, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases, today announced it will report SPY001 Part A induction topline results from the SKYLINE trial in moderate-to-severely active ulcerative colitis patients on Monday, April 13, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00am ET on Monday April 13, 2026 to discuss the results.

To access the live and archived webcast, please visit the Investor Relations page of Spyre’s website at https://ir.spyre.com/events-and-presentations.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

For more information, visit Spyre's website at www.spyre.com.

For Investors:
Eric McIntyre, Spyre Therapeutics
SVP of Finance and Investor Relations
Eric.mcintyre@spyre.com

For Media:
Josie Butler, 1AB
josie@1abmedia.com

FAQ

When will Spyre (SYRE) report SPY001 Part A topline results from SKYLINE?

Spyre will report SPY001 Part A topline results on Monday, April 13, 2026 at 8:00am ET. According to Spyre, the company will release induction topline data and host a conference call and webcast the same morning for investor discussion and Q&A.

How can investors access the Spyre (SYRE) conference call and webcast on April 13, 2026?

Investors can join the live webcast and access the archive via Spyre's Investor Relations website. According to Spyre, the event page at https://ir.spyre.com/events-and-presentations will host the live stream and a replay after the call.

What is SPY001 Part A in the SKYLINE ulcerative colitis trial (SYRE)?

SPY001 Part A is the induction cohort of Spyre's SKYLINE trial in moderate-to-severe ulcerative colitis. According to Spyre, Part A topline results will report initial efficacy and safety findings for the induction period on April 13, 2026.

Which patient population does the SKYLINE trial address for SPY001 (SYRE)?

The SKYLINE trial enrolled patients with moderate-to-severely active ulcerative colitis for SPY001 evaluation. According to Spyre, the topline Part A results reflect outcomes from that moderate-to-severe UC induction cohort.

What should shareholders expect from Spyre's (SYRE) April 13, 2026 conference call?

Shareholders should expect a topline data summary and management commentary regarding SPY001 Part A induction results. According to Spyre, management will discuss key findings, safety signals, and next steps during the 8:00am ET webcast and Q&A session.